Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease

Nilotinib is a broad‐based tyrosine kinase inhibitor with the highest affinity to inhibit Abelson (c‐Abl) and discoidin domain receptors (DDR1/2). Preclinical evidence indicates that Nilotinib reduces the level of brain alpha‐synuclein and attenuates inflammation in models of Parkinson's diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagan, Fernando L., Hebron, Michaeline L., Wilmarth, Barbara, Torres‐Yaghi, Yasar, Lawler, Abigail, Mundel, Elizabeth E., Yusuf, Nadia, Starr, Nathan J., Arellano, Joy, Howard, Helen H., Peyton, Margo, Matar, Sara, Liu, Xiaoguang, Fowler, Alan J., Schwartz, Sorell L., Ahn, Jaeil, Moussa, Charbel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412143/
https://www.ncbi.nlm.nih.gov/pubmed/30906562
http://dx.doi.org/10.1002/prp2.470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412143/
https://www.ncbi.nlm.nih.gov/pubmed/30906562
http://dx.doi.org/10.1002/prp2.470

Ejemplares similares